.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,171,370

« Back to Dashboard

Details for Patent: 4,171,370

Title: Phenoxy-amino-propanols
Abstract:New phenoxy-amino-propanols of formula ##STR1## wherein R.sup.1 is alkenyl, alkynyl, alkoxyalkyl or alkenyloxyalkyl with 2-6 C atoms in each case or cycloalkyl with 3-8 C atoms; and R.sup.2 is alkyl or hydroxyalkyl with 1-6 C atoms in each case, cycloalkyl with 3-8 C atoms, aralkyl or aralkyl wherein the aryl radical is mono- to tri-substituted by alkyl, alkoxy, OH, F and/or Cl or mono-substituted by methylenedioxy, with a total of 7-15 C atoms in each case, and the physiologically acceptable acid addition salts thereof, exhibit various pharmacological properties including isoprenaline-antagonism on the heart rate and blood pressure.
Inventor(s): Jonas; Rochus (Darmstadt, DE), Becker; Karl-Heinz (Darmstadt, DE), Enenkel; Hans-Joachim (Darmstadt, DE), Minck; Klaus (Darmstadt, DE), Schliep; Hans-Jochen (Darmstadt, DE)
Assignee: Merck Patent Gesellschaft mit beschrankter Haftung (Darmstadt, DE)
Filing Date:Oct 04, 1977
Application Number:05/839,487
Claims:1. Phenoxy-amino-propanols of the formula ##STR4## wherein R.sup.1 is alkenyl, alkynyl, alkoxyalkyl, alkenyloxyalkyl, with 2-6 C atoms in each case, or cycloalkyl with 3-8 C atoms; and R.sup.2 is aralkyl wherein the aryl radical is monosubstituted by methylenedioxy, with a total of 7-15 C atoms, and the physiologically acceptable acid addition salts thereof.

2. A pharmaceutical composition which comprises an amount of a compound of claim 1 effective for achieving isoprenaline-antagonism on the heart rate or blood pressure, and a pharmaceutically acceptable adjuvant.

3. A method of achieving isoprenaline-antagonism on the heart rate or blood pressure in a mammal, which comprises administering to a mammal an amount of a compound of claim 1 which is effective for achieving isoprenaline-antagonism on the heart rate or blood pressure.

4. 1-(o-2-Methoxyethoxymethyl-phenoxy)-3-[2-(3,4-methylenedio xyphenyl)-ethylamino]-propan-2-ol, a compound of claim 1.

5. A pharmaceutical composition which comprises an amount of a compound of claim 4 effective for achieving isoprenaline-antagonism on the heart rate or blood pressure, and a pharmaceutically acceptable adjuvant.

6. A method of achieving isoprenaline-antagonism on the heart rate or blood pressure in a mammal, which comprises administering to a mammal an amount of a compound of claim 4 which is effective for achieving isoprenaline-antagonism on the heart rate or blood pressure.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc